Which beta receptor subtype is primarily responsible for increased heart rate, contractility, and renin release?
Choose an answer, then check it.
Clinical Pharmacology · Adrenergic Agonists
Beta-Adrenergic Agonists
On this page 6 sections
In 30 seconds
Beta-adrenergic agonists activate beta-1, beta-2, and beta-3 receptors, which are all G-protein-coupled receptors that raise intracellular cyclic AMP. Beta-1 stimulation speeds and strengthens the heart, beta-2 stimulation relaxes smooth muscle in the airways, uterus, and blood vessels while shifting potassium into cells, and beta-3 stimulation relaxes the bladder detrusor muscle. These drugs are essential for treating shock, bronchospasm, and overactive bladder, but their biggest safety issue is that "selectivity" is dose-dependent — push the dose high enough and a beta-2-selective drug starts hitting beta-1 receptors too, causing tachycardia and palpitations.
The college version
Beta receptors are Gs-protein-coupled receptors. Agonist binding activates adenylyl cyclase, raising cyclic AMP, which in turn activates protein kinase A. The downstream effect depends entirely on which tissue the receptor sits in, which is why one receptor family produces such different effects across the body.
Beta-1 Receptors: The Heart
Beta-1 receptors predominate in cardiac tissue. Stimulation increases heart rate (positive chronotropy), contractility (positive inotropy), conduction velocity through the AV node (positive dromotropy), and automaticity of pacemaker cells (positive bathmotropy). Beta-1 receptors on the juxtaglomerular cells of the kidney also trigger renin release, linking sympathetic activation to the renin-angiotensin-aldosterone system. Dobutamine is the prototype beta-1-selective agonist, used for short-term inotropic support in cardiogenic shock or acute decompensated heart failure. Because it increases contractility with comparatively less increase in heart rate and peripheral resistance than nonselective agents, it is often preferred when the priority is improving cardiac output without proportionally raising myocardial oxygen demand. Even so, beta-1 selectivity is relative, not absolute — at higher exposures dobutamine can still cause tachycardia, arrhythmias, and increased myocardial oxygen consumption.
Beta-2 Receptors: Smooth Muscle and Metabolism
Beta-2 receptors are concentrated in bronchial smooth muscle, uterine smooth muscle, vascular smooth muscle of skeletal muscle beds, and the liver. Activation relaxes bronchial smooth muscle (bronchodilation), relaxes the uterus (tocolysis), dilates skeletal muscle vasculature, and stimulates hepatic and skeletal muscle glycogenolysis, which can raise blood glucose. Beta-2 stimulation also activates the sodium-potassium-ATPase pump, driving potassium into cells and lowering serum potassium — a mechanism used therapeutically in hyperkalemia and one that also explains why beta-2 agonist overuse can produce hypokalemia.
Short-acting beta-2 agonists (SABAs) such as albuterol and levalbuterol produce rapid bronchodilation and are used for quick relief of bronchospasm in asthma and COPD. Levalbuterol is the single active (R)-enantiomer isolated from racemic albuterol, marketed with the goal of similar efficacy with potentially fewer beta-1-mediated side effects, though clinical superiority over albuterol is modest. Long-acting beta-2 agonists (LABAs) such as salmeterol and formoterol have a longer duration of action and are used for maintenance bronchodilation, always paired with an inhaled corticosteroid rather than used alone, because LABA monotherapy in asthma has been associated with increased risk of severe exacerbations. Terbutaline is a beta-2 agonist historically used for bronchodilation and, off-label, for short-term tocolysis to delay preterm labor, though its uterine-relaxant use is limited by cardiovascular side effects and safety concerns with prolonged use. This subject treats the respiratory applications only at this overview level, since a dedicated respiratory pharmacology subject covers inhaled therapy in depth.
Isoproterenol is a nonselective beta agonist (beta-1 and beta-2, with no significant alpha activity) once used for bradyarrhythmias and bronchospasm. Its clinical use has narrowed considerably because it produces pronounced tachycardia and arrhythmia risk from unopposed beta-1 stimulation alongside beta-2 vasodilation, which can drop diastolic pressure. It remains conceptually important as the reference nonselective beta agonist against which selective agents are compared.
Beta-3 Receptors: The Bladder
Beta-3 receptors are found in the detrusor muscle of the bladder and in adipose tissue. Stimulation relaxes the detrusor during the bladder's filling phase, increasing bladder capacity without affecting the voiding contraction mediated by other pathways. Mirabegron, a beta-3-selective agonist, is used to treat overactive bladder with symptoms of urgency, frequency, and urge incontinence. Because it acts on smooth muscle relaxation rather than blocking cholinergic transmission, it avoids the dry mouth and constipation typical of antimuscarinic overactive-bladder drugs, though it can raise blood pressure and should be used cautiously with other adrenergic agents.
Adverse Effects and Nursing Considerations
Across the class, expect dose-related tachycardia, palpitations, and skeletal muscle tremor (from beta-2 stimulation of muscle spindles). Hypokalemia and transient hyperglycemia are predictable with beta-2 agonists and warrant monitoring in patients with cardiac disease or diabetes. Selectivity is never absolute: as systemic exposure rises, beta-1-selective and beta-2-selective drugs increasingly stimulate the "off-target" receptor, so a patient on a high-dose beta-2 agonist can still develop significant cardiac stimulation. Paradoxical bronchospasm — acute airway tightening immediately after inhaled beta-2 agonist use — is a rare but important reaction requiring the inhaler be stopped and an alternative bronchodilator considered. Nursing priorities include monitoring heart rate, rhythm, and blood pressure; monitoring serum potassium and glucose with repeated or high-dose beta-2 agonist use; assessing for tremor and anxiety; using cardiac monitoring with intravenous agents like dobutamine or isoproterenol; and teaching patients that increasing SABA use signals worsening disease control rather than a reason to simply use more.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of your heart, lungs, and bladder as machines with the same kind of "on" switch, called a beta receptor, but each machine does something different when that switch flips. Flip the switch in the heart (beta-1) and it beats faster and harder — like pressing the gas pedal. Flip it in the lungs (beta-2) and the airways open wider — like loosening a tight collar so you can breathe easier; the same switch also nudges sugar and potassium around in your blood. Flip it in the bladder (beta-3) and the muscle around it relaxes so it can hold more before you feel the urge to go. Medicines like dobutamine mostly hit the heart switch, medicines like albuterol mostly hit the lung switch, and mirabegron mostly hits the bladder switch — but "mostly" is the key word. Give too much of any of them, and it starts flipping the other switches too, which is why high doses of an asthma inhaler can make your heart race and your hands shake.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient receiving an intravenous dobutamine infusion for cardiogenic shock develops new tachycardia and occasional ectopic beats as the infusion rate is increased. Explain why this happens even though dobutamine is described as beta-1-selective.
Show answer
Selectivity is dose-dependent, so higher doses drive beta-1 harder and spill over onto other receptors.
Dobutamine mostly hits beta-1 switches at typical infusion rates, but no drug is perfectly one-switch-only — as the dose (and blood level) climbs, it starts triggering beta-1 receptors even harder and can nudge other receptors too, which is exactly why faster infusions bring on tachycardia and extra heartbeats; the nurse should recognize this as an expected dose-related effect to watch for and report, not a separate new problem.
A patient using a long-acting beta-2 agonist inhaler alone, without any inhaled corticosteroid, asks why their provider wants to add a second medication. Explain the pharmacologic and safety reasoning behind pairing a LABA with an inhaled corticosteroid rather than using the LABA by itself.
Show answer
LABA monotherapy is linked to worse asthma outcomes, so it's paired with an anti-inflammatory.
A LABA only relaxes airway muscle — it doesn't calm the underlying airway inflammation that drives asthma, so using it alone can mask worsening disease while the inflammation continues unchecked, which has been linked to more severe flare-ups; adding an inhaled corticosteroid treats that inflammation directly, which is why guidelines pair the two rather than allowing LABA-only treatment.
Quick check
3 questions here. Answers stay hidden until you check.
A patient using a short-acting beta-2 agonist inhaler far more often than prescribed reports muscle weakness. Which electrolyte abnormality should the nurse suspect?
Choose an answer, then check it.
Which drug is a beta-3-selective agonist used for overactive bladder?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.